아시아 태평양 증후군 멀티플렉스 진단 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

아시아 태평양 증후군 멀티플렉스 진단 시장 – 2029년까지의 산업 동향 및 예측

  • Medical Devices
  • Published Report
  • May 2022
  • Asia-Pacific
  • 350 Pages
  • 테이블 수: 111
  • 그림 수: 43

>아시아 태평양 증후군 멀티플렉스 진단 시장, 제품 및 서비스별(시약 및 소모품, 기기, 소프트웨어 및 액세서리 및 서비스), 감염 유형(바이러스, 박테리아, 기생충 및 진균), 질병(호흡기 감염, 위장염, 성병, 패혈증, 뇌막염 및 기타), 패널 유형(호흡기 패널, GI-장 패널, 성병 패널, 혈액-패혈증 패널, 뇌막염 패널 및 기타), 최종 사용자(임상 실험실, 병원, 제약 및 생명공학 회사, 연구소 및 기타) 산업 동향 및 2029년까지의 예측

아시아 태평양 증후군 멀티플렉스 진단 시장

시장 정의 및 통찰력

증후군 멀티플렉스 진단은 호흡기 감염, 감염성 위장염, 성병 , 패혈증, 수막염과 같은 다양한 유형의 감염성 질환을 감지하는 데 사용되는 일종의 고급 진단 검사입니다 . 증후군 멀티플렉스 진단은 또한 임상의 또는 병원이 다양한 유형의 질병의 증상과 징후를 감지하는 데 도움이 됩니다. 이를 통해 의료 서비스 제공자는 환자에게 올바른 치료를 제공하고 보다 정확한 결과와 보다 빠르게 수행할 수 있는 치료를 제공할 수 있습니다.

증후군 멀티플렉스 진단 시장

증후군 멀티플렉스 진단 시장

증후군 멀티플렉스 검사는 여러 병원체를 동시에 진단하는 데 사용됩니다. 증후군 멀티플렉스 진단에서는 다양한 유형의 시약 및 소모품과 기구 및 액세서리가 사용되어 정확성을 유지하고 빠른 진단 결과를 제공합니다. 이러한 멀티플렉스 검사는 특정 감염을 빠르게 진단하여 임상 관리 결정을 신속하게 내릴 수 있습니다. 멀티플렉스 기술에 기반한 검사는 검사 패널이라고 합니다. 증후군 검사에 사용되는 패널은 동일하거나 유사한 유형의 증후군과 관련된 여러 질병을 진단하도록 설계되었습니다. 이러한 패널은 치료 시점에서 질병의 원인을 평가하는 데 도움이 됩니다. 위장관 패널과 호흡기 패널은 증후군 패널의 유형입니다.

증후군 멀티플렉스 검사는 멀티플렉스 PCR의 첨단 기술을 활용하여 정확하고 빠른 진단 결과를 제공하고, 증후군 멀티플렉스 진단에 사용되는 다중 패널을 사용하여 1시간 이내에 진단 결과를 제공합니다. 새로운 세대의 증후군 멀티플렉스는 호흡기 검체, 혈액 및 뇌척수액에서 흔한 병원균 유형을 빠르게 식별할 수 있습니다. 멀티플렉스 패널을 사용하면 처리 시간이 단축되고 불필요한 다른 실험실 검사가 줄어들고 진단이 더 빨라지며 표적 치료가 가능합니다.

Data Bridge Market Research에 따르면 아시아 태평양 증후군 멀티플렉스 진단 시장이 2022년부터 2029년까지의 예측 기간 동안 연평균 성장률 9.6%로 성장할 것으로 분석됩니다.

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 연도

2020

양적 단위

매출은 백만 달러, 볼륨은 단위, 가격은 달러로 표시됨

다루는 세그먼트

Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection Type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others),  Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis Panel and Others),  End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others)

Countries Covered

China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific

Market Players Covered

BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc. (South Korea), Luminex Corporation. A DiaSorin Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cepheid (A subsidiary of Danaher (U.S.)), QIAGEN (Germany), Abbott (U.S.), Hologic, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Siemens Healthcare GmbH (Germany), Biocartis (Belgium), QuantuMDx Group Ltd. (U.K.), Prominex Inc. (U.S.), Curetis (A subsidiary of OpGen, Inc.) (Germany), MiRXES Pte Ltd (Singapore)

Syndromic Multiplex Diagnostic Market Dynamics

Drivers

  • Increasing demand for fast and accurate results

Fast and accurate syndromic diagnostic helps healthcare professionals to provide efficient medication at the proper time. Accurate syndromic diagnostic testing is used for various pathogens in a single test reaction. This test helps provide more comprehensive, accurate, and realistic results in critical care. Hence, the high demand for fast and accurate results drives the market growth.

  • Rise in prevalence of infectious diseases

The rising incidence of infectious bacterial and viral diseases impacts the market's demand because, in the syndromic testing, multiplex real-time PCR technique and the syndromic approach are used for molecular diagnostics of infectious diseases.

Opportunity

  • Rising Diagnostic Healthcare Expenditure

The growing healthcare expenditure is expected to increase the availability of services and affordability for the population to opt for better and more precise diagnostic services to manage their diseases. The increase in healthcare expenditure ensures better availability of diagnostic services. Hence, huge health care expenditure is a favourable factor and is acting as an opportunity for the growth of the syndromic multiplex diagnostic market.

Restraints/Challenges

  • High Cost of Diagnostic Products

The multiplex syndromic testing applications utilize the real-time Polymerase chain reaction (PCR), which delivers the results with amplification curves and correct values. The instruments used in the syndromic multiplex diagnostic require high maintenance costs. Hence, the high cost of instruments is a challenge for the market.

Post COVID-19 Impact on Syndromic Multiplex Diagnostic market

COVID-19 has positively affected the market. Market players are launching different products for the detection of the SARS-CoV virus. There is an increase in approval of products by regulatory bodies after post COVID-19, which leads to a rise in market growth.

Recent Development

  • In January 2022, QIAGEN announced the enhancements in the commercialization of the QIAstat-Dx syndromic testing menu. This enhancement will help the company increase its revenue in the coming years.

Syndromic Multiplex Diagnostic Market Scope

The syndromic multiplex diagnostic market is categorized into five segments: product and services, infection type, disease, panels type, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Services

  • Reagents & Consumables
  • Instruments, Software & Accessories
  • Services

Based on products and services, the Asia-Pacific syndromic multiplex diagnostic market is segmented into reagents & consumables, instruments, software & accessories and services.

Infection Type

  • Viral
  • Bacterial
  • Parasites
  • Fungal

Based on infection type, the Asia-Pacific syndromic multiplex diagnostic market is segmented into viral, bacterial, parasites and fungal

Disease

  • Respiratory Infection
  • Gastroneteritis
  • Sexually Transmitted Infections
  • Sepsis
  • Meningitis
  • Others

Based on disease, the Asia-Pacific syndromic multiplex diagnostic market is segmented into respiratory infections, gastroenteritis, sexually transmitted infections, sepsis meningitis and others

Panels Type

  • Respiratory Panel
  • GI-Enteric Panel
  • Sexually Transmitted Disease Panel
  • Blood-Sepsis Panel
  • Meningitis Panel
  • Others

Based on panels type, the Asia-Pacific syndromic multiplex diagnostic market is segmented into respiratory panel, GI-enteric panel, sexually transmitted disease panel, blood-sepsis panel, meningitis panel and others

End User

  • Hospitals
  • Clinical Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Research Institutes
  • Others

증후군 멀티플렉스 진단 시장

Based on end user, the Asia-Pacific syndromic multiplex diagnostic market is segmented into clinical laboratories, hospitals, pharmaceutical & biotechnology companies, research institutes and others

Syndromic Multiplex Diagnostic Market Regional Analysis/Insights

The syndromic multiplex diagnostic market is analyzed, and market size insights and trends are provided by country, product and services, infection type, disease, panels type and end user, as referenced above.

The countries covered in the report are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific.

중국 증후군 멀티플렉스 진단 시장은 감염병 유병률 증가와 조기 정확한 진단에 대한 수요 증가로 인해 성장할 것으로 예상됩니다. 또한, 글로벌 기업들이 신제품을 출시하려는 이니셔티브가 증가함에 따라 예측 기간 동안 시장 성장이 더욱 촉진될 것입니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

증후군 멀티플렉스 진단 시장 점유율 분석

증후군 멀티플렉스 진단 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 사우디 아라비아의 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 제공된 위의 데이터 포인트는 증후군 멀티플렉스 진단 시장과 관련된 회사의 초점에만 관련이 있습니다.

아시아 태평양 증후군 멀티플렉스 진단 시장에서 활동하는 주요 기업으로는 BioFire Diagnostics(bioMérieux SA의 자회사), Seegene Inc., Luminex Corporation. DiaSorin Company, F. Hoffmann-La Roche Ltd, BD, Bio-Rad Laboratories, Inc., Cepheid(Danaher의 자회사), QIAGEN, Abbott, Hologic, Inc., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Biocartis, QuantuMDx Group Ltd., Prominex Inc, Curetis(OpGen, Inc.의 자회사), MiRXES Pte Ltd. 등이 있습니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT AND SERVICES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S FIVE FORCES

4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021)

5 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES

6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES

6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING

6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS

6.2 RESTRAINTS

6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS

6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS

6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE

6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS

6.4 CHALLENGES

6.4.1 PRODUCT RECALLS

6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS

7 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES

7.1 OVERVIEW

7.2 REAGENTS & CONSUMABLES

7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES

7.4 SERVICES

8 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE

8.1 OVERVIEW

8.2 VIRAL

8.2.1 CORONAVIRUS

8.2.2 INFLUENZA VIRUS

8.2.3 ADENOVIRUS

8.2.4 RHINOVIRUS

8.2.5 ROTAVIRUS

8.2.6 OTHERS

8.3 BACTERIAL

8.3.1 PNEUMONIAE

8.3.2 BORDETELLA PERTUSSIS

8.3.3 STAPHYLOCOCCUS

8.3.4 OTHERS

8.4 PARASITES

8.5 FUNGAL

9 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE

9.1 OVERVIEW

9.2 RESPIRATORY INFECTIONS

9.3 GASTROENTERITIS

9.4 SEXUALLY TRANSMITTED INFECTIONS

9.5 SEPSIS

9.6 MENINGITIS

9.7 OTHERS

10 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE

10.1 OVERVIEW

10.2 RESPIRATORY PANEL

10.3 GI-ENTERIC PANEL

10.4 SEXUALLY TRANSMITTED DISEASE PANEL

10.5 BLOOD-SEPSIS PANEL

10.6 MENINGITIS PANEL

10.7 OTHERS

11 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 CLINICAL LABORATORIES

11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

11.5 RESEARCH INSTITUTES

11.6 OTHERS

12 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION

12.1 ASIA-PACIFIC

12.1.1 CHINA

12.1.2 JAPAN

12.1.3 INDIA

12.1.4 SOUTH KOREA

12.1.5 AUSTRALIA

12.1.6 SINGAPORE

12.1.7 THAILAND

12.1.8 MALAYSIA

12.1.9 INDONESIA

12.1.10 PHILIPPINES

12.1.11 REST OF ASIA-PACIFIC

13 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMÉRIEUX SA)

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 COMPANY SHARE ANALYSIS

15.1.4 PRODUCT PORTFOLIO

15.1.5 RECENT DEVELOPMENTS

15.2 F. HOFFMANN-LA ROCHE LTD

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENT

15.3 LUMINEX CORPORATION. A DIASORIN COMPANY

15.3.1 COMPANY SNAPSHOT

15.3.2 RECENT FINANCIALS

15.3.3 COMPANY SHARE ANALYSIS

15.3.4 PRODUCT PORTFOLIO

15.3.5 RECENT DEVELOPMENT

15.4 CEPHEID (A SUBSIDIARY OF DANAHER)

15.4.1 COMPANY SNAPSHOT

15.4.2 RECENT FINANCIALS

15.4.3 COMPANY SHARE ANALYSIS

15.4.4 PRODUCT PORTFOLIO

15.4.5 RECENT DEVELOPMENTS

15.5 QIAGEN

15.5.1 COMPANY SNAPSHOT

15.5.2 RECENT FINANCIALS

15.5.3 COMPANY SHARE ANALYSIS

15.5.4 PRODUCT PORTFOLIO

15.5.5 RECENT DEVELOPMENT

15.6 ABBOTT

15.6.1 COMPANY SNAPSHOT

15.6.2 REVENUE ANALYSIS

15.6.3 PRODUCT PORTFOLIO

15.6.4 RECENT DEVELOPMENT

15.7 AKONNI BIOSYSTEMS, INC.

15.7.1 COMPANY SNAPSHOT

15.7.2 PRODUCT PORTFOLIO

15.7.3 RECENT DEVELOPMENT

15.8 APPLIED BIOCODE, INC.

15.8.1 COMPANY SNAPSHOT

15.8.2 PRODUCT PORTFOLIO

15.8.3 RECENT DEVELOPMENTS

15.9 BD

15.9.1 COMPANY SNAPSHOT

15.9.2 REVENUE ANALYSIS

15.9.3 PRODUCT PORTFOLIO

15.9.4 RECENT DEVELOPMENTS

15.1 BIOCARTIS

15.10.1 COMPANY SNAPSHOT

15.10.2 REVENUE ANALYSIS

15.10.3 PRODUCT PORTFOLIO

15.10.4 RECENT DEVELOPMENT

15.11 BIO-RAD LABORATORIES, INC.

15.11.1 COMPANY SNAPSHOT

15.11.2 REVENUE ANALYSIS

15.11.3 PRODUCT PORTFOLIO

15.11.4 RECENT DEVELOPMENT

15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH)

15.12.1 COMPANY SNAPSHOT

15.12.2 REVENUE ANALYSIS

15.12.3 PRODUCT PORTFOLIO

15.12.4 RECENT DEVELOPMENT

15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.)

15.13.1 COMPANY SNAPSHOT

15.13.2 RECENT FINANCIALS

15.13.3 PRODUCT PORTFOLIO

15.13.4 RECENT DEVELOPMENTS

15.14 HOLOGIC, INC.

15.14.1 COMPANY SNAPSHOT

15.14.2 RECENT FINANCIALS

15.14.3 PRODUCT PORTFOLIO

15.14.4 RECENT DEVELOPMENT

15.15 MIRXES PTE LTD.

15.15.1 COMPANY SNAPSHOT

15.15.2 PRODUCT PORTFOLIO

15.15.3 RECENT DEVELOPMENT

15.16 NANŌMIX, INC.

15.16.1 COMPANY SNAPSHOT

15.16.2 PRODUCT PORTFOLIO

15.16.3 RECENT DEVELOPMENT

15.17 PROMINEX INC.

15.17.1 COMPANY SNAPSHOT

15.17.2 PRODUCT PORTFOLIO

15.17.3 RECENT DEVELOPMENT

15.18 QUANTUMDX GROUP LTD.

15.18.1 COMPANY SNAPSHOT

15.18.2 PRODUCT PORTFOLIO

15.18.3 RECENT DEVELOPMENTS

15.19 SEEGENE INC.

15.19.1 COMPANY SNAPSHOT

15.19.2 REVENUE ANALYSIS

15.19.3 PRODUCT PORTFOLIO

15.19.4 RECENT DEVELOPMENTS

15.2 SIEMENS HEALTHCARE GMBH

15.20.1 COMPANY SNAPSHOT

15.20.2 RECENT FINANCIALS

15.20.3 PRODUCT PORTFOLIO

15.20.4 RECENT DEVELOPMENT

15.21 THERMOFISHER SCIENTIFIC INC.

15.21.1 COMPANY SNAPSHOT

15.21.2 RECENT FINANCIALS

15.21.3 PRODUCT PORTFOLIO

15.21.4 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

표 목록

TABLE 1 COST OF THE PRODUCT

TABLE 2 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 3 ASIA PACIFIC REAGENTS & CONSUMABLES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC INSTRUMENTS, SOFTWARE & ACCESSORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 ASIA PACIFIC SERVICES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC PARASITES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC FUNGAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC RESPIRATORY INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC GASTROENTERITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC SEXUALLY TRANSMITTED INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC SEPSIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC MENINGITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 ASIA PACIFIC OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 21 ASIA PACIFIC RESPIRATORY PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 ASIA PACIFIC GI-ENTERIC PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 ASIA PACIFIC SEXUALLY TRANSMITTED DISEASE PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 ASIA PACIFIC BLOOD-SEPSIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 ASIA PACIFIC MENINGITIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 ASIA PACIFIC OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 ASIA PACIFIC HOSPITALS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 ASIA PACIFIC CLINICAL LABORATORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 ASIA PACIFIC PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 ASIA PACIFIC RESEARCH INSTITUTES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 ASIA PACIFIC OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 34 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 35 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 36 ASIA-PACIFIC VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 37 ASIA-PACIFIC BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 38 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 39 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 40 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 42 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 43 CHINA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 44 CHINA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 45 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 46 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 47 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 48 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 49 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 50 JAPAN VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 51 JAPAN BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 52 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 53 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 54 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 55 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 56 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 57 INDIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 58 INDIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 59 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 60 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 61 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 62 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 63 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 64 SOUTH KOREA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 65 SOUTH KOREA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 66 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 67 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 68 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 69 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 70 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 71 AUSTRALIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 72 AUSTRALIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 73 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 74 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 75 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 76 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 77 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 78 SINGAPORE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 79 SINGAPORE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 80 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 81 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 82 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 83 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 84 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 85 THAILAND VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 86 THAILAND BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 87 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 88 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 89 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 90 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 91 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 92 MALAYSIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 93 MALAYSIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 94 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 95 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 96 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 97 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 98 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 99 INDONESIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 100 INDONESIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 101 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 102 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 103 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 104 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

TABLE 105 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 106 PHILIPPINES VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 107 PHILIPPINES BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)

TABLE 108 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)

TABLE 109 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)

TABLE 110 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 111 REST OF ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)

그림 목록

FIGURE 1 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: END USER COVERAGE GRID

FIGURE 9 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES IS EXPECTED TO DRIVE THE ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD

FIGURE 12 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET

FIGURE 15 TOTAL CASES OF COVID-19 IN NORTH AMERICA

FIGURE 16 TOTAL CASES OF COVID-19 IN EUROPE

FIGURE 17 NATIONAL HEALTH EXPENDITURE VS MEDICAL DEVICE EXPENDITURE, U.S., 2019

FIGURE 18 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2021

FIGURE 19 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2022-2029 (USD MILLION)

FIGURE 20 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, CAGR (2022-2029)

FIGURE 21 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE

FIGURE 22 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2021

FIGURE 23 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2022-2029 (USD MILLION)

FIGURE 24 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2022-2029)

FIGURE 25 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE

FIGURE 26 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2021

FIGURE 27 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2022-2029 (USD MILLION)

FIGURE 28 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2022-2029)

FIGURE 29 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE

FIGURE 30 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2021

FIGURE 31 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2022-2029 (USD MILLION)

FIGURE 32 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2022-2029)

FIGURE 33 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE

FIGURE 34 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2021

FIGURE 35 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 36 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029)

FIGURE 37 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021)

FIGURE 39 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021)

FIGURE 40 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029)

FIGURE 41 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029)

FIGURE 42 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029)

FIGURE 43 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

China is the dominating region of the Asia-Pacific Syndromic Multiplex Diagnostic Market.
The Asia-Pacific Syndromic Multiplex Diagnostic Market growth rate will be 9.6% by 2029.
Rise in prevalence of infectious diseases, Increasing demand for fast and accurate results are the growth drivers of the Asia-Pacific Syndromic Multiplex Diagnostic Market.
The product and services, infection type, disease, panels type, and end-user product and services, infection type, disease, panels type, and end user.
The major companies in the Asia-Pacific Syndromic Multiplex Diagnostic Market are BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc., Luminex Corporation. A DiaSorin Company, F. Hoffmann-La Roche Ltd, BD, Bio-Rad Laboratories, Inc., Cepheid (A Subsidiary of Danaher), QIAGEN, Abbott, Hologic, Inc., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Biocartis, QuantuMDx Group Ltd., Prominex Inc, Curetis (A Subsidiary of OpGen, Inc.), MiRXES Pte Ltd.